Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug

AI technology is expected to help make it faster and easier for Mytesi^® patients to start and stay on the drug

SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company is developing an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

"We remain committed to reducing access and reimbursement barriers for Mytesi patients. One key challenge we often hear from patients and their healthcare providers is that payers and insurance companies frequently require prior authorization to approve medication reimbursement, and it can be time consuming and complicated to provide the needed information," said Ian H. Wendt, Jaguar's Chief Commercial Officer. "Artificial intelligence (AI) technology, like OpenAI's generative AI language model ChatGPT, is an innovative and powerful tool that allows providers to expeditiously communicate their professional judgment by significantly reducing the time and complexity of drafting letters of medical necessity. We are working to create a user-friendly, ChatGPT-enabled interface to help make this otherwise burdensome process easier and faster for healthcare providers to navigate in a compliant way."

According to a December 2021 American Medical Association (AMA) survey of 1,004 practicing U.S. physicians, an overwhelming majority (88%) of participants reported that the prior authorization (PA) process interferes with continuity of care, and 84% reported that the number of PAs required for prescription medications and medical services had increased over the last five years. The AMA survey also found that 93% of participating physicians reported care delays while waiting for insurers to authorize necessary care, 82% said a PA can lead to treatment abandonment because of PA struggles with the patient's insurance company, and almost one in five prescriptions require a PA.